康方生物 (9926 HK; 75港元; 目标价: 112.6港元) 依沃西单抗全球III期试验结果发布康方生物及其合作伙伴Summit Therapeutics (SMMT US)上周五更新了依沃西单抗全球III期临床试验HARMONi研究的初步数据。海外试验数据与去年在中国开展的III期HARMONi-A试验结果基本一致,符合预期。尽管数据与预期一致,但投资者对结果的反应较为担忧,主要是因为...
Source Link康方生物 (9926 HK; 75港元; 目标价: 112.6港元) 依沃西单抗全球III期试验结果发布康方生物及其合作伙伴Summit Therapeutics (SMMT US)上周五更新了依沃西单抗全球III期临床试验HARMONi研究的初步数据。海外试验数据与去年在中国开展的III期HARMONi-A试验结果基本一致,符合预期。尽管数据与预期一致,但投资者对结果的反应较为担忧,主要是因为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.